Home > Publications Database > Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. > print

001     137844
005     20240321220327.0
024 7 _ |a 10.1212/WNL.0000000000001399
|2 doi
024 7 _ |a pmid:25716354
|2 pmid
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
024 7 _ |a altmetric:3737812
|2 altmetric
037 _ _ |a DZNE-2020-04166
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wolfsgruber, Steffen
|0 P:(DE-2719)2810544
|b 0
|e First author
|u dzne
245 _ _ |a Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI.
260 _ _ |a [S.l.]
|c 2015
|b Ovid
264 _ 1 |3 online
|2 Crossref
|b Ovid Technologies (Wolters Kluwer Health)
|c 2015-02-25
264 _ 1 |3 print
|2 Crossref
|b Ovid Technologies (Wolters Kluwer Health)
|c 2015-03-24
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1591364842_14017
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To test whether, in individuals with mild cognitive impairment (MCI), different measures of subjective cognitive decline (SCD) in the memory domain predict abnormal CSF biomarkers of Alzheimer disease (AD).We analyzed the multicenter baseline (cross-sectional) data of 245 patients with MCI. SCD was measured quantitatively with the Subjective Memory Decline Scale (SMDS) and qualitatively by assessing particular concerns associated with self-experienced worsening of memory. Logistic regression models were used to examine associations between SCD and abnormal CSF biomarkers, taking into account objective memory impairment, depressive symptoms, and education as covariates.Abnormal CSF β-amyloid 1-42 (Aβ42) and more depressive symptoms were associated with higher SMDS scores and with the report of memory concerns. Risk of abnormal CSF Aβ42 increased by an estimated 57% for a 1-SD increase in SMDS scores and was doubled in patients who had SMDS scores >4 or who reported memory concerns, respectively. In addition, both SCD measures predicted risk of having a biomarker signature indicative of prodromal AD defined as presence of low CSF Aβ42 together with either high CSF tau or CSF phosphorylated tau 181 levels.In MCI, specific aspects of SCD severity and quality are related to CSF biomarkers indicative of AD. This extends findings in pre-MCI samples and calls for an improved operational assessment of SCD in MCI. This might be useful for sample enrichment strategies for increased likelihood of AD pathology.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Peptide Fragments
|2 NLM Chemicals
650 _ 7 |a amyloid beta-protein (1-42)
|2 NLM Chemicals
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: physiopathology
|2 MeSH
650 _ 2 |a Alzheimer Disease: psychology
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: physiopathology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: psychology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Memory Disorders: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Memory Disorders: physiopathology
|2 MeSH
650 _ 2 |a Memory Disorders: psychology
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Peptide Fragments: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Prodromal Symptoms
|2 MeSH
650 _ 2 |a tau Proteins: cerebrospinal fluid
|2 MeSH
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 1
|u dzne
700 1 _ |a Koppara, Alexander
|0 P:(DE-2719)2813437
|b 2
|u dzne
700 1 _ |a Kleineidam, Luca
|0 P:(DE-2719)2812139
|b 3
|u dzne
700 1 _ |a Schmidtke, Klaus
|b 4
700 1 _ |a Frölich, Lutz
|b 5
700 1 _ |a Kurz, Alexander
|b 6
700 1 _ |a Schulz, Stefanie
|b 7
700 1 _ |a Hampel, Harald
|b 8
700 1 _ |a Heuser, Isabella
|b 9
700 1 _ |a Peters, Oliver
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Reischies, Friedel M
|b 11
700 1 _ |a Jahn, Holger
|b 12
700 1 _ |a Luckhaus, Christian
|b 13
700 1 _ |a Hüll, Michael
|b 14
700 1 _ |a Gertz, Hermann-Josef
|b 15
700 1 _ |a Schröder, Johannes
|b 16
700 1 _ |a Pantel, Johannes
|b 17
700 1 _ |a Rienhoff, Otto
|b 18
700 1 _ |a Rüther, Eckart
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Henn, Fritz
|b 20
700 1 _ |a Wiltfang, Jens
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Maier, Wolfgang
|0 P:(DE-2719)2000015
|b 22
|u dzne
700 1 _ |a Kornhuber, Johannes
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 24
|e Last author
|u dzne
773 1 8 |a 10.1212/wnl.0000000000001399
|b : Ovid Technologies (Wolters Kluwer Health), 2015-02-25
|n 12
|p 1261-1268
|3 journal-article
|2 Crossref
|t Neurology
|v 84
|y 2015
|x 0028-3878
773 _ _ |a 10.1212/WNL.0000000000001399
|g Vol. 84, no. 12, p. 1261 - 1268
|0 PERI:(DE-600)1491874-2
|n 12
|q 84:12<1261 - 1268
|p 1261-1268
|t Neurology
|v 84
|y 2015
|x 0028-3878
909 C O |o oai:pub.dzne.de:137844
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810544
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2813437
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812139
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)2000015
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2000057
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|2 G:(DE-HGF)POF3-300
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2015
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROLOGY : 2017
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 0
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Patient studies cologne
|x 1
920 1 _ |0 I:(DE-2719)7000001
|k U Clinical Researchers - Bonn
|l U Clinical Researchers - Bonn
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)7000001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21